Skip to main content
European Commission logo print header

Training the next-generation of European GLIOblastoma (translational) researchers, to RESOLVE precision targeting of the brain tumour microenvironment

Project description

Precision medicine targets glioblastoma

Developing effective precision medicine therapies for glioblastoma (GBM) is a challenge due to the complexity and heterogeneity of this aggressive and lethal form of primary brain tumour. Precision medicine uses targeted therapies tailored to the specific molecular characteristics of individual tumours. However, it is difficult to target GBM, which is known for its heterogeneous tumour microenvironment (TME). In this context, the EU-funded GLIORESOLVE project seeks to extend immunotherapy options to GBM patients, identify novel TME subtype-specific therapeutic targets, develop and optimise preclinical models and test novel drug combinations for precision treatment of GBM based on TME subtype assignment. To this aim, GLIORESOLVE will train 10 innovative and entrepreneurial doctoral candidates through multi-sectoral collaborations in innovative research disciplines.


Isocitrate dehydrogenase wildtype (IDHwt) glioblastoma (GBM) is the most frequent, aggressive and lethal brain tumour. It has a universally fatal prognosis with 85% of patients dying within two years. Effective precision medicine therapies are thus urgently required. This can only be achieved by focused multi-sectoral collaborations in innovative research disciplines. Overall, GLIORESOLVE will exploit the intractability of GBM to address European applied biomedical research training needs and will train 10 innovative, entrepreneurial doctoral researchers (DRs). The research objectives of GLIORESOLVE are i) to extend immunotherapy options to IDHwt GBM patients and identify novel tumour microenvironment (TME) subtype-specific therapeutic targets, (ii) develop and optimise state of the art pre-clinical models that recapitulate GBM TME-subtypes and (iii) test novel rationally selected (available) drugs / drug combinations for precision treatment of IDHwt GBM based on TME subtype assignment. Cumulatively, the programme seeks to generate sufficient data to support a post-project Phase 2 clinical trial. The consortium brings together leading European academics, clinicians, private sector and not-for-profit partners, and incorporates disruptive research methods including multi-omics, ex-vivo ‘tumour-on-a-chip’ assay development, computational modelling and systems biology. Overall GLIORESOLVE provides a comprehensive translational research strategy that goes significantly beyond the current state-of-the-art in neuro-oncology, to establish a new TME-targeting precision medicine platform for this incurable disease. The GLIORESOLVE network addresses current needs in academia and the private sector to train doctoral researchers in an environment that spans multiple disciplines. Thus, GLIORESOLVE DRs will be able to navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.


Net EU contribution
€ 286 488,00
2 Dublin

See on map

Ireland Northern and Western Border
Activity type
Higher or Secondary Education Establishments
Total cost
No data

Participants (9)

Partners (11)